Skip to Content
Merck
CN

L8533

Lansoprazole

≥98% (TLC), Gastric proton pump inhibitor, powder

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C16H14F3N3O2S
CAS Number:
103577-45-3
Molecular Weight:
369.36
UNSPSC Code:
12352200
PubChem Substance ID:
24278520
NACRES:
NA.77
MDL number:
MFCD00866873
Assay:
≥98% (TLC)
Form:
powder
Quality level:
100

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Lansoprazole, ≥98% (TLC), powder

Quality Level

100

assay

≥98% (TLC)

form

powder

color

off-white

originator

Novartis

storage temp.

2-8°C

SMILES string

Cc1c(CS(=O)c2nc3ccccc3[nH]2)nccc1OCC(F)(F)F

InChI

1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)

InChI key

MJIHNNLFOKEZEW-UHFFFAOYSA-N

Gene Information

human ... ATP4A(495), ATP4B(496)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Biochem/physiol Actions

Gastric proton pump inhibitor.

Features and Benefits

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCL0034
BCCC6217
BCBT8114
BCBP0690V
BCBP0690

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

T B Bödvarsdóttir et al.
Diabetologia, 53(10), 2220-2223 (2010-06-30)
Gastrin has been implicated in islet growth/neogenesis, and proton pump inhibitors (PPIs) have been shown to increase endogenous gastrin levels in animals and humans. Therefore, we investigated the effect of PPIs in a model of type 2 diabetes, Psammomys obesus.
Lin Ye et al.
Journal of cellular and molecular medicine, 25(5), 2703-2713 (2021-02-20)
Acute kidney injury (AKI) is the main obstacle that limits the use of cisplatin in cancer treatment. Proton pump inhibitors (PPIs), the most commonly used class of medications for gastrointestinal complications in cancer patients, have been reported to cause adverse
Sayed M Derayea et al.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 209, 209-216 (2018-11-07)
Cytochrome P450 (CYP) is a class of heme-containing enzymes which mainly catalyze a monooxygenation reaction of various chemicals, and hence CYP plays a key role in the drug metabolism. Although CYP2C19 isoform is a minor hepatic CYP, it metabolizes clinically
L B Barradell et al.
Drugs, 44(2), 225-250 (1992-08-01)
Lansoprazole is an effective acid pump inhibitor acting at the final enzymatic step of the acid secretory pathway of the parietal cell, decreasing gastric acid secretion regardless of the primary stimulus. Results of short term (less than 8 weeks) clinical
Hala H Mosli et al.
The Journal of clinical endocrinology and metabolism, 97(9), E1731-E1735 (2012-06-23)
Chromogranin A (CgA) is used as a generic tumor marker for neuroendocrine tumors. Proton pump inhibitors (PPI) are known to increase CgA, but it is not clear to what extent, and there is little information on how long PPI need
View All Related Papers

Global Trade Item Number

SKUGTIN
L8533-1G04061833966075
L8533-250MG04061833966082

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service